Zollinger-Ellison syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Zollinger-Ellison syndrome}}
{{Zollinger-Ellison syndrome}}
{{CMG}} {{AE}} {{MJK}}
==Overview==
The incidence of [[gastrinoma]] is approximately 0.5-2/million population/year worldwide.<ref name="pmid22261919">{{cite journal| author=Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P et al.| title=ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. | journal=Neuroendocrinology | year= 2012 | volume= 95 | issue= 2 | pages= 98-119 | pmid=22261919 | doi=10.1159/000335591 | pmc=PMC3701449 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22261919  }} </ref>. About 25 to 30 percent of gastrinomas, which can cause Zollinger-Ellison syndrome, are caused by  multiple endocrine neoplasia type 1 ([[MEN1]]).<ref name="NIDDK">National Institute of Diabetes and Digestive and Kidney Diseases.http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/zollinger-ellison-syndrome/Pages/facts.aspx#causes</ref>


Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 20:05, 26 September 2015

Zollinger-Ellison syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Zollinger-Ellison syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Zollinger-Ellison syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Zollinger-Ellison syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Zollinger-Ellison syndrome epidemiology and demographics

CDC on Zollinger-Ellison syndrome epidemiology and demographics

Zollinger-Ellison syndrome epidemiology and demographics in the news

Blogs on Zollinger-Ellison syndrome epidemiology and demographics

Directions to Hospitals Treating Zollinger-Ellison syndrome

Risk calculators and risk factors for Zollinger-Ellison syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

The incidence of gastrinoma is approximately 0.5-2/million population/year worldwide.[1]. About 25 to 30 percent of gastrinomas, which can cause Zollinger-Ellison syndrome, are caused by multiple endocrine neoplasia type 1 (MEN1).[2]

References

  1. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P; et al. (2012). "ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes". Neuroendocrinology. 95 (2): 98–119. doi:10.1159/000335591. PMC 3701449. PMID 22261919.
  2. National Institute of Diabetes and Digestive and Kidney Diseases.http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/zollinger-ellison-syndrome/Pages/facts.aspx#causes

Template:WH Template:WS